The Role of Enteroviruses

An Old Suspect, Revisited

For many people with ME/CFS, the illness begins with what feels like a perfectly ordinary infection: a bout of gastroenteritis, a respiratory illness, a fever that never quite resolves the way it should. Weeks pass. Then months. The fatigue deepens, the cognitive fog thickens, and the person who once ran half-marathons or worked a full day without a second thought finds themselves unable to manage a short walk without triggering days of collapse. What started the chain reaction?

One hypothesis that has persisted — through cycles of serious interest and frustrating dismissal — is that a group of viruses called enteroviruses may be a significant trigger for ME/CFS in a meaningful subset of patients. The idea is not new. Early reports raised the possibility decades ago, only to be largely shelved when the science to test them properly didn't yet exist. More recent work, equipped with better tools and harder data, has brought the hypothesis back to the table with renewed urgency.

What Are Enteroviruses, and Why Would They Matter Here?

Enteroviruses are a large and diverse family of viruses — humans are susceptible to more than 70 distinct types — responsible for a wide range of illnesses, from the common cold to hand, foot and mouth disease, viral meningitis, and acute gastroenteritis. They are transmitted primarily through the gut and respiratory tract, and for most people in most circumstances, infection is self-limiting: unpleasant, brief, and then over.

But the critical word is most. Under certain conditions, enteroviruses are capable of something more troubling: establishing a persistent, low-level infection that the immune system cannot fully clear. Laboratory experiments in cell cultures and in animal models have shown that enteroviruses can form double-stranded RNA — a molecular signature of viral replication — and sustain a chronic state in host tissue long after the acute illness appears to have resolved. It is a biological mechanism that mirrors, with uncomfortable precision, what researchers have found when examining tissue samples from ME/CFS patients.

This matters because ME/CFS is characterised not just by profound fatigue but by signs of ongoing immune activation: elevated inflammatory markers, dysregulated immune cell behaviour, and a pattern that looks far less like post-viral recovery and far more like a body still locked in a fight it cannot win. The question researchers have been pressing is: what, exactly, is it still fighting?

The Evidence: Gut Biopsies, Immune Stalemates, and Infectious Triggers

Some of the most compelling enterovirus research in this field has come from studies focused on the gastrointestinal tract — a finding that resonates strongly with patients, given that gut symptoms are among the most commonly reported but frequently overlooked features of ME/CFS.

In a landmark 2008 study, researcher John Chia examined gut tissue biopsies from ME/CFS patients and found a high prevalence of enteroviral proteins and genetic material in those samples. This was significant for two reasons. First, it offered a plausible anatomical reservoir — a place where the virus could hide and persist, evading full immune clearance. Second, it provided a biological explanation for the gastrointestinal symptoms that many patients experience but that clinicians have often struggled to account for.

A follow-up study in 2010 took the argument further. Chia proposed a model in which acute enteroviral infection can produce what amounts to an immunological stalemate: the virus is not eliminated, but neither is it replicating freely. This state of chronic persistence, the research suggested, may be precisely what underpins the sustained immune dysfunction observed in ME/CFS. It is a delicate and deeply uncomfortable equilibrium — the body caught in a standoff that produces ongoing symptoms without a clearly identifiable active pathogen.

In the same year, a separate study by researcher Zhang linked enterovirus to a specific subtype of ME/CFS and identified it — alongside Epstein-Barr virus, another long-suspected culprit — as one of the two most commonly identified infectious precipitants of the condition. The convergence of these lines of evidence began to look less like coincidence and more like a signal worth taking seriously.

What This Could Mean for Understanding ME/CFS

The enterovirus hypothesis carries significant implications — not just for understanding what causes ME/CFS, but for how it might one day be treated and, crucially, diagnosed. ME/CFS currently has no confirmed diagnostic biomarker: diagnosis depends on clinical criteria and the often lengthy process of ruling out other conditions. If a subset of ME/CFS cases can be definitively linked to persistent enteroviral infection, that opens the door to targeted testing, better-defined patient subgroups, and, eventually, antiviral treatment trials designed around a specific biological mechanism rather than symptom management alone.

There is already some suggestive evidence in this direction. Some ME/CFS patients have reported improvement on antiviral medications — responses that, while far from universal and not yet backed by large-scale controlled trials, are at least consistent with the idea that ongoing viral activity is contributing to their illness. Hemispherx Biopharma, for instance, has investigated immune-modulating approaches for ME/CFS, reflecting a broader scientific interest in tackling the condition through its immunological roots.

It is equally important to be clear about what the evidence does not yet show. No single study has established a causal relationship between enteroviral infection and ME/CFS. The research to date — gut biopsies, in vitro models, epidemiological associations — is compelling as a body of converging evidence, but causation is a high bar, and the field has been burned before by premature certainty. ME/CFS research has a complicated history of promising findings that did not replicate, and rigorous scepticism remains a methodological virtue. What can be said with confidence is that enteroviruses represent a biologically plausible, evidence-supported candidate — one that warrants sustained, well-funded investigation using the tools now available to modern virology and immunology.

Where the Research Goes from Here

The enterovirus hypothesis is part of a broader and accelerating effort to understand ME/CFS as what the evidence increasingly suggests it is: a serious, biological illness with measurable physical underpinnings, not a psychological condition or a problem of perception. Institutions including the National Institutes of Health have in recent years significantly increased their investment in ME/CFS research, and international networks such as the European Network on ME/CFS (EUROMENE) have worked to coordinate and consolidate findings across research centres in Europe.

In Australia, Griffith University's National Centre for Neuroimmunology and Emerging Diseases (NCNED), based in Queensland, has been a significant contributor to the biological understanding of ME/CFS — particularly in areas of immune dysfunction and ion channel abnormalities. The global picture is one of genuine scientific momentum, with researchers in multiple countries pursuing the viral, immunological, and neurological threads that may, taken together, finally explain what is happening in the bodies of the millions of people living with this illness.

For patients, the enterovirus story is both validating and, for now, incomplete. It supports what many have long suspected — that their illness began with a real infection and that something biological may be sustaining it — while stopping short of the therapeutic breakthrough they are waiting for. That breakthrough requires more research: more biopsies, more controlled trials, more funding, and more of the sustained scientific attention that ME/CFS has historically struggled to command. The evidence is building. The question is how quickly the field can move from hypothesis to answers.